Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹321 Cr
Revenue (TTM)
₹156 Cr
Net Profit (TTM)
₹8 Cr
ROE
9.3 %
ROCE
13.2 %
P/E Ratio
39.4
P/B Ratio
2.9
Industry P/E
35.17
EV/EBITDA
18.2
Div. Yield
0 %
Debt to Equity
0.5
Book Value
₹70.2
EPS
₹5.2
Face value
10
Shares outstanding
15,583,120
CFO
₹6.50 Cr
EBITDA
₹68.52 Cr
Net Profit
₹39.45 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Infinium
| -7.6 | -2.5 | -8.4 | -13.8 | -- | -- | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Infinium
| -27.4 | 30.8 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Infinium
|
206.0 | 321.0 | 155.7 | 7.8 | -- | 9.3 | 39.4 | 2.9 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
2003
Chairman
--
Managing Director
Sanjay Kumar Patel
Headquarters
Anand Dist, Gujarat
Website
Looking for more details about Infinium Pharmachem Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Infinium Pharmachem Ltd is ₹206.00 (NSE) as of 02-Apr-2026 IST. Infinium Pharmachem Ltd has given a return of -13.81% in the last 1 years.
The P/E ratio of Infinium Pharmachem Ltd is 39.41 times as on 02-Apr-2026, a 12 premium to its peers’ median range of 35.17 times.
The P/B ratio of Infinium Pharmachem Ltd is 2.93 times as on 02-Apr-2026, a 9 discount to its peers’ median range of 3.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.28
|
3.44
|
|
2024
|
28.20
|
5.42
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Infinium Pharmachem Ltd are Rs 337.00 and Rs 189.40 as of 05-Apr-2026.
Infinium Pharmachem Ltd has a market capitalisation of ₹ 321 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Infinium Pharmachem Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.